WHO Introduces HPV Single-Dose Vaccine to Boost Cervical Cancer Elimination Efforts

By João L. Carapinha

October 6, 2024

The article from the World Health Organization (WHO) titled “WHO adds an HPV vaccine for single-dose use” highlights important advancements in the global initiative to combat cervical cancer through HPV vaccination, specifically through the introduction of a new single-dose HPV vaccine (SD-HPV Vac). This milestone aims to transform how girls are vaccinated against cervical cancer, particularly in regions with limited access to healthcare. Here are the key points:

New Single-Dose HPV Vaccine

The WHO has prequalified a fourth HPV vaccine product, Cecolin®, for use in a single-dose schedule. This decision is based on new data that meets the criteria set out in the WHO’s 2022 recommendations for alternative, off-label use of HPV vaccines in single-dose schedules.

Impact on Supply and Accessibility

The addition of this HPV vaccine will help address the ongoing global supply challenges for HPV vaccines, which have been hampered by shortages since 2018. This will enable more girls to be vaccinated against cervical cancer, particularly in low- and middle-income countries.

Global Strategy for Cervical Cancer Elimination

The WHO aims to have 90% of girls fully vaccinated with the HPV vaccine by the age of 15 as part of its global strategy for cervical cancer elimination. The single-dose HPV vaccine is expected to facilitate achieving this target.

Public Health Benefits

Cervical cancer is a preventable disease, with over 95% of the 660,000 annual cases globally caused by HPV. Every two minutes, a woman dies from cervical cancer, with 90% of these deaths occurring in low- and middle-income countries. The new SD-HPV Vac will help reduce these alarming statistics.

Funding and Commitments

There has been significant funding committed towards the elimination of cervical cancer. This includes nearly US$ 600 million from various partners, such as the Bill & Melinda Gates Foundation (US$ 180 million), UNICEF (US$ 10 million), and the World Bank (US$ 400 million).

Implementation and Coverage

As of September 10, 2024, 57 countries are implementing the HPV vaccine schedule, up from 37 countries in 2023. The adoption of the SD-HPV Vac schedule has resulted in at least 6 million additional girls being reached with HPV vaccines in 2023.

Technical and Regulatory Aspects

The single-dose use indication for Cecolin® is included in the second edition of WHO’s technical document on considerations for HPV vaccine product choice. Public health advisory bodies can recommend “off-label” use of vaccines when supported by data and clear public health benefits, until manufacturers update their labels.

Overall, the introduction of the SD-HPV Vac marks a significant step forward in the global effort to eliminate cervical cancer, enhancing vaccine accessibility and addressing supply challenges effectively.

Reference url

Recent Posts

Canada Drug Agency Plan
          

Canada Drug Agency Plan: Shaping the Future of Health Systems 2025-2030

🚀 Are you ready to explore the future of healthcare in Canada?

The newly launched **Canada Drug Agency Plan** aims to redefine how we approach drug and health technology decisions, focusing on anticipation, innovation, and transformation to boost health outcomes for all Canadians. This five-year strategic initiative captures essential insights needed for a healthier nation amid evolving pharmaceutical policies.

Curious how this plan could impact the healthcare landscape? Dive into the full article to learn more!

#SyenzaNews #HealthcarePolicy #HealthTech #Innovation

hepatitis C treatment options
       

VIETNARMS Trial Unveils Innovative Hepatitis C Treatment Options

🔍 Are you curious about the latest advancements in hepatitis C treatment options?

The groundbreaking VIETNARMS trial reveals that sofosbuvir-daclatasvir offers a comparable efficacy to sofosbuvir-velpatasvir while exploring innovative strategies that could reshape treatment accessibility and affordability. With cure rates exceeding 90%, these findings hold promise for improving outcomes, especially in underserved populations.

Dive into the full article to uncover how these developments could revolutionize hepatitis C care!

#SyenzaNews #globalhealth #HealthcareInnovation

hepatitis C treatment
    

Revolutionizing Hepatitis C Treatment: The Transformative Role of Direct-Acting Antivirals

💡 How are direct-acting antivirals (DAAs) revolutionizing hepatitis C treatment?

The rise of DAAs has led to cure rates between 95-99%, shifting the landscape of hepatitis C care. As we strive for the global eradication goal by 2030, understanding the market dynamics and expanding patient access becomes crucial.

Dive into the article to explore how these advancements impact health economics and public health strategies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.